News and blogs
282 results found.
A
Ardsad
Test
Test
Helen Rowntree appointed Blood Cancer UK’s chief executive
Blood Cancer UK has announced Helen Rowntree as its new permanent chief executive.
How we’re planning to make people more aware of blood cancer
Why do people diagnosed with blood cancer often leave with less knowledge of their condition compared to other cancers? We're tackling that question and outlining what we can do to raise the profile of blood cancer as a health condition.
Blood Cancer UK funding led to understanding the origins of childhood leukaemia in twins
New research has shed light on the origins on a type of blood cancer – childhood acute lymphoblastic leukaemia – and how it develops in children.
New ‘universal approach’ therapy for leukaemia shows promise during world-first trial
Blood Cancer UK was proud to fund the lab studies that directly led to this life-changing trial which could broaden the number of people who benefit from this type of therapy in future.
Test
This is a test
Evusheld available in the UK to buy privately
Evusheld is available privately in the UK. Here’s what we know about how to access it.
New campaign launches for the forgotten 500,000 families
Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after Covid-19 lockdown. The campaign is calling for the Government to reverse its decision and immediately roll out Evusheld for the immunosuppressed.
Health inequalities: how does stress change our bodies?
You might not have heard of "allostatic load" before, but scientists are learning more and more about how chronic stress adds to the ‘wear and tear’ on our bodies, the way it differs between ethnicities and leads to health inequality.
Charles R. Drew - Blood Pioneer
For Black History Month, we are celebrating Charles R. Drew who was an African American surgeon and researcher who pioneered in the field of blood transfusions, blood storage and created the first blood banks.
Sidney Farber - The Father of Modern Chemotherapy
Dr Sidney Farber was an American paediatric pathologist. He discovered the role folic acid played in the creation of leukaemia cells and achieved the first clinical remission of leukaemia in children by using a chemical anti agent.
Chief Executive Gemma Peters announces her departure
We are sad to announce that our chief executive, Gemma Peters, will be leaving Blood Cancer UK.
Celebrating September
For Blood Cancer Awareness Month, Jonathan shares his story in memory of his dad Ian whose MGUS developed into Acute Myeloid Leukaemia. Ian sadly died in May 2022; just 8 weeks after his diagnosis.
Remembering Her Majesty the Queen
Over half of UK adults unable to name single blood cancer symptom
As we enter Blood Cancer Awareness Month, we're highlighting the massive crisis of awareness in blood cancer. Despite blood cancer being the UK’s third biggest cancer killer, one in four people would be unlikely to go to their GP if they had any of the main symptoms
What's the latest on Evusheld?
Many people living with blood cancer will be deeply disappointed by the news that the Government will not make Evusheld available until an appraisal (a full assessment) of the drug has been completed. We are also devastated by this announcement and are continuing to campaign for it to be bought and made available on the NHS immediately. Here's an update on what we’re doing, along with some information about the context of the Government's decision.
Facts and information about blood cancer
Blood cancer is the UK’s third biggest cancer killer, and yet awareness and understanding of it is much lower than for other types of cancer.
Five things we learned about blood cancer services from the Cancer Patient Experience Survey
Every year, NHS England asks thousands of cancer patients in England about their experiences. We've picked out five key things we think the NHS and Government should be focusing on, which we believe would save a significant number of lives.
Over 120 leading clinicians have signed a clinical consensus statement, declaring that the Covid-19 protective antibody treatment Evusheld should be used as soon as possible to protect people most vulnerable to Covid-19.
Over 120 leading clinicians have signed a clinical consensus statement, declaring that the Covid-19 protective antibody treatment Evusheld should be used as soon as possible to protect people most vulnerable to Covid-19.
